Marstacimab: First Approval.

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Yvette N Lamb

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: New Zealand : Drugs , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 716071

Thêm vào giỏ Liên kết toàn văn

Marstacimab (marstacimab-hncq
HYMPAVZI™) is a subcutaneously administered human monoclonal immunoglobulin G1 antibody against tissue factor pathway inhibitor (TFPI) that is being developed by Pfizer for the treatment of hemophilia A and B. Marstacimab received its first approval on 11 October 2024 in the USA. It was approved for use as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors. Marstacimab has since been approved on 18 Nov in the EU for the treatment of adults and adolescents with severe hemophilia A or B without inhibitors. This article summarizes the milestones in the development of marstacimab leading to this first approval for hemophilia.

Tạo bộ sưu tập với mã QR